How Caffeine Works: Adenosine Receptors Explained

Sleep is guided by two major forces: adenosine accumulation and circadian rhythm. Adenosine is a substance that accumulates in the brain over time, creating sleep pressure—the longer you stay awake, the more adenosine accumulates and the stronger the sleep pressure becomes. The circadian rhythm is a biological clock measured by cortisol peaks in the morning, melatonin peaks at night, and body temperature changes. These two forces work together to regulate when you feel sleepy. The circadian rhythm can be modified by environmental factors, with light being the strongest modifier.

Two principal factors regulate wakefulness and sleep: the circadian rhythm (body's 24-hour clock) and adenosine (a chemical that builds up during wakefulness). The circadian rhythm, controlled by the suprachiasmatic nucleus in the hypothalamus, regulates moods, eating preferences, core body temperature, hormone release, athletic performance, and even birth/death timing. Melatonin, produced by the pineal gland, signals the body to prepare for sleep at dusk and its release is halted by dawn sunlight. Adenosine progressively accumulates while awake, creating sleep pressure that decreases during sleep. The combined effects of these two systems create the daily wake-sleep cycle, explaining why people feel alert at noon after good sleep but sleepy at midnight. Individual differences exist, with morning larks feeling energized in the morning while night owls function best at night.

Sleep pressure depends on adenosine, a purine molecule produced by neurons during their activity. Adenosine accumulates in the body over time, acting like a 'key' that opens 'sleep receptors' in the brain. After 12-14 hours of wakefulness, this accumulation signals the pineal gland to begin producing melatonin to prepare the body for sleep. The accumulation process creates the natural sleepiness that builds throughout the day.

Sleep is regulated by two mechanisms: circadian rhythm (melatonin signaling rest time) and sleep pressure (adenosine accumulation). Melatonin production is regulated by light exposure—daylight suppresses it, evening darkness increases it. Adenosine accumulates during wakefulness, creating sleep pressure. Both must be present for effective sleep onset. Light exposure, even small amounts, can suppress melatonin.

Sleep is a fundamental biological process that humans lose consciousness for one-third of each day. Consciousness may be an emergent property of complex neural processes that cease during sleep. Sleep is nearly universal among animals, from amphibians to humans, including birds, mammals, bats, and even sharks, which sleep in sections of their brain. The circadian rhythm, regulated by the suprachiasmatic nucleus (SCN), follows a 26-hour cycle synchronized with light and darkness. Body temperature rises around 5-6 AM and reaches its lowest point between 3-4 AM. Adenosine accumulates throughout the day, creating sleep pressure that peaks at sleep time. Sleep alternates between REM and non-REM phases every 90 minutes, with REM sleep focusing on tissue repair and memory consolidation, while non-REM sleep involves muscle paralysis and active visual processing.

Methylxanthines are naturally occurring alkaloids found in tea (Thea sinensis) and coffee (Coffea Arabica), with three main forms: caffeine (1,3,7-trimethylxanthine), theophylline (1,3-dimethylxanthine), and theobromine (1,7-dimethylxanthine). These drugs act as CNS stimulants, cardiac stimulants, bronchodilators (by inhibiting phosphodiesterase and increasing cAMP), and have mild diuretic properties. Theophylline is the most commonly used methylxanthine in clinical practice, particularly for COPD management, though it is considered a third or fourth-line drug due to the availability of more effective alternatives like beta-agonists and corticosteroids. Methylxanthines have a narrow therapeutic index and require careful monitoring, with important drug interactions including enzyme inducers (phenytoin, phenobarbital, rifampicin) that increase metabolism and enzyme inhibitors (erythromycin, cimetidine, ciprofloxacin) that decrease metabolism and increase toxicity risk.

Methylxanthines are compounds with bronchodilatory properties, including caffeine, theophylline, and theobromine. Theophylline has the most significant bronchodilatory effects, while caffeine has minimal respiratory effects. Both are CNS stimulants that increase alertness and skeletal muscle contractility. They have complex cardiovascular effects: caffeine decreases heart rate (due to vagus nerve stimulation), while theophylline increases heart rate (due to direct cardiac effects). These systemic effects are important considerations when using methylxanthines.

Methylxanthines are xanthine derivatives with methyl groups at specific positions: caffeine (1,3,7-trimethyl), theophylline (1,3-dimethyl), and theobromine (3,7-dimethyl). They are found naturally in coffee and tea. These compounds are narrow therapeutic index drugs where small dose changes can shift between therapeutic and toxic ranges. Systemic effects include CNS stimulation (nervousness, insomnia, convulsions), cardiovascular stimulation (increased heart rate, blood pressure), mild diuresis, muscle contraction, increased gastric acid secretion, and increased basal metabolic rate. They also inhibit mast cell degranulation, providing some anti-inflammatory benefit in asthma. Theophylline is available as 100-600mg tablets/capsules (not water-soluble, no injection form), while aminophylline is water-soluble and available as tablets and IV infusion.

Methylxanthines exert diverse pharmacological effects: CNS stimulation causing nervousness, insomnia, and convulsions; GI tract stimulation increasing gastric acid and digestive enzyme secretion; renal effects producing weak diuretic action; and smooth muscle effects including bronchodilation and improved skeletal muscle contractility. Clinically, these drugs have a narrow therapeutic index requiring blood level monitoring. Clearance decreases in liver disease while smoking induces hepatic enzymes, increasing clearance. Oral theophylline controls mild to moderate chronic asthma, while intravenous aminophylline treats status asthmaticus when sympathomimetics fail, though methylxanthines are generally less effective than sympathomimetic bronchodilators.

Methylxanthines (theophylline, caffeine, theobromine) exert diverse physiological effects: CNS stimulation producing alertness at therapeutic doses but nervousness/insomnia at high doses; cardiovascular stimulation causing tachycardia (theophylline) or bradycardia (caffeine) with arrhythmia risk; smooth muscle relaxation with potent bronchodilation (theophylline > caffeine); mild diuretic action via sodium/water inhibition; skeletal muscle enhancement via calcium release; CTZ stimulation causing nausea; and mast cell stabilization reducing histamine release. Blood pressure effects are unpredictable due to opposing vasomotor and vagal influences.

Caffeine has diverse therapeutic applications: neonatal apnea treatment (safest stimulant for newborns), migraine treatment (vasodilatory effects counteract vasoconstrictive migraine mechanisms), and adjunct to analgesics (potentiates pain relief). Caffeine-containing analgesics are widely used for headaches. For ADHD treatment, psychostimulants like methylphenidate are preferred over amphetamines in Russia.

Methylxanthines (caffeine and theophylline) serve as the mainstay pharmacological treatment for apnea of prematurity through competitive inhibition of adenosine receptors. Adenosine acts as an inhibitory neuromodulator of respiratory drive, and blocking its receptors increases ventilatory responsiveness to carbon dioxide and reverses central hypoxic depression. Additional peripheral effects include enhanced diaphragmatic contraction and improved pharyngeal muscle tone. Caffeine offers advantages over theophylline including longer half-life, higher therapeutic index, fewer side effects (less tachycardia and GI effects), and no requirement for drug level monitoring. The loading dose for caffeine citrate is 20 mg/kg (up to 40 mg/kg for multiple episodes), with maintenance at 5 mg/kg every 24 hours, adjustable based on weight gain and clinical response.

Caffeine citrate is used to treat apnea of prematurity, a condition where premature infants have periods of stopped breathing. Caffeine stimulates the respiratory center in the brainstem and has been shown to reduce the frequency and severity of apnea episodes. The typical dose is equivalent to about 10 cups of coffee per day for an adult, but administered intravenously to premature infants. Caffeine therapy provides multiple benefits beyond treating apnea, including improved neurodevelopmental outcomes and reduced need for mechanical ventilation. Maternal caffeine consumption during pregnancy does not appear to have significant adverse effects on the fetus.

Management includes prone positioning with neutral neck, elevated crib, and neutral temperature. Skin stimulation is performed during episodes, with manual ventilation if unresponsive. Differential diagnosis includes infections, respiratory alterations, airway anomalies, Pierre Robin syndrome, Down syndrome, neuromuscular diseases, necrotizing enterocolitis, metabolic disorders, CNS lesions, medications, and hematological conditions. Laboratory evaluation includes CBC, cultures, PCR, thermal stability assessment, pulse oximetry, chest X-ray, hematocrit, and hemoglobin. Metabolic evaluation includes glucose, calcium, and electrolytes. Caffeine is the safest and most used drug, with loading dose 20 mg/kg and maintenance 5 mg/kg/day (up to 10 mg/kg/day for low birth weight). It increases lung volume, functional residual capacity, oxygenation, and stimulates respiratory centers. Alternative medications include aminophylline and theophylline. Caffeine has longer half-life (up to 120 hours), easier dosing, higher toxic threshold, and fewer side effects. For persistent apnea, high-flow nasal cannula or positive pressure ventilation may be needed. Short-term effects include reduced cerebral blood flow and potential hyperperfusion. Long-term effects are difficult to study due to confounding pathologies, though caffeine therapy showed better neurological outcomes at 18-21 months.

Treatment includes non-pharmacological and pharmacological approaches. Non-pharmacological treatment involves proper head positioning in a neutral position (neither hyperextended nor flexed) to maintain airway patency, stimulation of the infant, and non-invasive ventilation such as CPAP or nasal intermittent positive pressure ventilation for obstructive apnea. Pharmacological treatment primarily uses methylxanthines, with caffeine being most commonly used due to favorable side effects. Caffeine works by inhibiting adenosine receptors, increasing cyclic AMP and cyclic GMP, activating potassium channels, and blocking calcium channels, which enhances chemoreceptor sensitivity to CO2 and increases diaphragmatic contractility. The loading dose is 20 mg/kg with maintenance of 5-10 mg/kg. Caffeine can be discontinued when infants reach 34-35 weeks gestational age with no apnea episodes for at least 7 days.